DR
Dermata Therapeutics, Inc.
DRMA · NASDAQ
$1.07 -4.46% (-$0.05)
1M -11.57%
Market Cap $4.30M
P/E Ratio -
Div. Yield -
ROE 166.67%
Bulios Fair Price
$0.81
24.3% downside
Current Price
$1.07
Undervalued Fair Value Overvalued
According to Bulios Fair Price, DRMA is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
1/9Valuation
100 /100
Cheap P/B 1.23x
PEG N/A
P/E N/A
Growth
31 /100
Declining Book val. growth 1.10%
FCF growth N/A
EPS growth N/A
Profitability
-
N/A Op. margin N/A
Gross margin N/A
FCF margin N/A
Quality
0 /100
Poor ROA 157.28%
ROIC 246.61%
Asset turnover 0.00x
Debt
100 /100
Low Current ratio 2.81x
Debt/Equity 0.00x
Debt/Assets N/A
Stability
37 /100
Moderate Profitable years 0
Beta 0.69x
EPS volatility 157.17%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about DRMA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Gerald T. Proehl
Employees
9
Headquarters
San Diego
Upcoming events
18 NOV
Earnings
Upcoming earnings report